These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29239578)

  • 1. National vaccination program - a success story of public health and economy.
    Salo H; Kilpi T
    Duodecim; 2017; 133(10):977-83. PubMed ID: 29239578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informing vaccine decision-making: A strategic multi-attribute ranking tool for vaccines-SMART Vaccines 2.0.
    Knobler S; Bok K; Gellin B
    Vaccine; 2017 Jan; 35 Suppl 1():A43-A45. PubMed ID: 28017435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a routine varicella vaccination program for US children.
    Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
    JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considering economic analyses in the revision of the preventive vaccination law: a new direction for health policy-making in Japan?
    Akazawa M; Yongue J; Ikeda S; Satoh T
    Health Policy; 2014 Oct; 118(1):127-34. PubMed ID: 25139708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decision making process on new vaccines introduction in South Africa.
    Ngcobo NJ; Cameron NA
    Vaccine; 2012 Sep; 30 Suppl 3():C9-13. PubMed ID: 22939028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.